

SPONSORSHIP AGREEMENT

This sponsorship agreement (the "Agreement") is made effective as of 30.03.2019 (the "Effective Date"), between Swedish Orphan Biovitrum A/S, Sorgenfrivej 17, 2800 Lyngby ("Sobi") and Danmarks Bløderforening, Kompaniestræde 22, 2. Sal, 1208 København K ("Recipient").

WHEREAS, Sobi A/S is an affiliate of an international biopharmaceutical company dedicated to rare diseases;

WHEREAS, Recipient is Patient Organization and

WHEREAS, Sobi has agreed to sponsor the participation of 1 member from the Danish P.O. in the European Haemophilia Consortium First European Conference on Bleeding Disorders October 4.-6., 2019 in Skopje, Macedonia

NOW, THEREFORE, the parties agree as follows:

1. TERMS AND CONDITIONS OF SPONSORSHIP

- 1.1 **Sponsorship:** Sobi hereby agrees to provide Recipient the sum of 6.860 DKK (six-thousand-eight-hundred-sixty 00/00) (the "Sponsorship").
- 1.2 **Scope:** The Sponsorship shall only cover actual, documented, reasonable and direct costs that are necessary in order to carry out the professional parts of the Meeting, as further specified in Schedule 1. Activities and materials generated as a result of this Sponsorship shall comply with all applicable laws and regulations.
- 1.3 **Meeting Budget and Repayment:** Recipient shall provide Sobi with a complete budget for the Meeting. Actual costs for the parts sponsored by Sobi shall be reported to Sobi no later than 15.09.2019. Unused budget resources shall be repaid to Sobi without delay after the Meeting or immediately if the Meeting is cancelled.
- 1.4 **Benefits of Sponsorship:** In return for Sobi sponsoring the Meeting Recipient shall provide Sobi with the benefits specified in Schedule 2.
- 1.5 **Payment:** The Sponsorship will be paid in the following by bank transfer: 7040-1106847. Danmarks Bløderforening mrk: EHC
- 1.6 **Payment Terms:** All payments hereunder shall be made within thirty (30) days from receipt of invoice provided that the following conditions shall have been met: invoices shall be specified as to Sobi contact person Julie Trolle, cost center Haemophilia.

Sobi's invoice address is: Sorgenfrivej 17, 2800 Lyngby.

- 1.7 **Communication:** Well before the Meeting, Recipient shall communicate the names of all sponsors. Sobi will be transparent regarding its support of the Meeting and the Recipient agrees to be similarly transparent. The Sponsorship will be acknowledged by the Recipient and made clear on all materials as further specified in Schedule 2. Participants' invitations shall state the Recipient as the organizer, the purpose of the Meeting activities and identify as sponsors Sobi and any other pharmaceutical companies which sponsor the Meeting
- 1.8 **Use of Sobi name:** Recipient shall only use the name and logotypes of Sobi, in publications, presentations, programmes, other printed or orally presented materials or otherwise, after prior review and approval of Sobi.
- 1.9 **No inducement:** Recipient acknowledges that provision of the Sponsorship is in no way an inducement to recommend, prescribe, purchase, supply, sell or administer a particular medicinal product.
- 1.10 Hospitality, programme and venue of the Meeting: Enclosed. The Recipient represents and warrants to Sobi that
- (a) Hospitality made directly or indirectly available during the Meeting shall be kept at a reasonable level and remain secondary to the principal scientific purpose of the Meeting, be limited to the organisation and/or defrayment of the costs of travel, meals, accommodation and registration, shall not extend beyond the official duration of the Meeting and shall not include payment for or the organization of sports or leisure activities or any other form of entertainment;
- (b) The value of meals provided, drinks included, shall not exceed the limits laid down by Applicable Law, including applicable local industry guidelines;
- (c) The Meeting shall be predominantly scientific in nature and activities with a scientific purpose shall, in terms of time, take up the greater part of each day of the Meeting; and
- (d) The Meeting shall take place at a suitable venue that aids the scientific purpose of the event and the place, date and duration of the Meeting and travel shall not in any case be of a nature to create any confusion as to its scientific nature.

2. MISCELLANEOUS PROVISIONS

- 2.1 **Entire Agreement:** This Agreement, including its Schedules, constitutes the entire understanding between the parties with respect to the subject matter hereof

and supersedes all prior oral or written agreements of the parties with respect to such subject matter

- 2.2 **Amendments:** No provision of this Agreement may be amended, modified or otherwise changed, other than by an instrument in writing duly executed on behalf of the parties to this Agreement.
- 2.3 **Assignments:** This Agreement is personal to the parties who shall not have any right to assign it without the prior written consent of the other party, except that Sobi shall have the right to assign the Agreement to its affiliates.
- 2.4 **Independent Contractors:** In making and performing this Agreement, the parties are acting and shall act at all times as independent contractors, and nothing contained in this Agreement shall be construed or implied to create any agency, partnership or employer and employee relationship between Sobi and Recipient. At no time shall any party make commitments or incur any charges or expenses for or in the name of any other party, other than as expressly set forth herein.
- 2.5 **Transfer of Value Disclosure Codes:** Recipient acknowledges that any transfer of value ("ToV") made by or on behalf of Sobi pursuant to this Agreement may be reported to government entities or other third parties as required by law or industry codes and that Sobi may disclose such payments on its website or as otherwise required by such laws or codes. Recipient shall assist Sobi in its compliance with applicable laws, regulations and transparency principles with respect to such transfer of value and will provide any information necessary to comply with any reporting as required by applicable law or industry code.
- 2.6 **Governing Law and Jurisdiction:** This Agreement shall be governed and construed by the substantive laws of Denmark. Any dispute, controversy or claim arising out of or in connection with this Agreement, or the breach, termination or invalidity thereof, shall be finally settled by the courts of the above said country.


[Signatures to follow on the next page.]

This Agreement has been signed by each party's duly authorized signatory(ies). This Agreement may be executed and transmitted via email in Portable Document Format (PDF), and in counterparts, each of which taken together, shall constitute one agreement binding on the parties with the same force and effect as an original signed agreement.

Mai Clifford, Sobi


Name: Mai Clifford
Title: GM Denmark & Iceland
Date: 18/9-2019

Karen Binger Holm, Danmarks Bløderforening


Name: Karen Binger Holm
Title: CEO
Date: 2/10-19

SPONSORSHIP AND COSTS

Application and budget:

Danmarks Bløderforening
Kompagnistræde 22, 2. sal baghuset
1208 København K
Tlf. 3314 5505
www.bloderforeningen.dk

Den 13. september 2019

Sobi

Ansøgning om støtte til deltagelse i EHC konference 2019

Danmarks Bløderforening vil med denne ansøgning søge Sobi om støtte til at sende en repræsentant til EHC konference d. 4-6. oktober 2019 i Skopje, Nordmakedonien. Der er i det internationale blødersamfund en stærk solidaritet og tradition for at dele viden og erfaring om livet med blødersygdom. Ligeledes er international forskning afgørende for udvikling og optimering af bløderbehandlingen, også i Danmark. Internationale møder og konferencer er vigtige arenaer for at opnå ny viden og udbygge relationer og derfor prioriterer Danmarks Bløderforening deltagelse højt.

I år sender Danmarks Bløderforening fire repræsentanter til EHC konferencen i Bruxelles. Delegationen skal blandt andet skabe opmærksomhed om det danske værtsskab for EHC konferencen i København i 2020.

Vedlagt er program for EHC konferencen. Med denne ansøgning søges om støtte til at dække deltagergebyr, rejse, ophold og lokal transport for en deltager:

Budget DKR

Deltagergebyr 200 Euro	1.493 kr.
Ibis Hotel City Centre 3 nætter	1.567 kr.
Fly Tur/retur	3.000 kr.
Transport lokalt Estimat	800 kr.
I alt	<u>6.860 kr.</u>

Foreningen dækker omkostning til deltageres rejseforsikring.

Enhver støtte er velkommen og modtages med tak. Kontakt mig gerne, hvis der er spørgsmål til ansøgningen.

Venlig hilsen
Karen Binger Holm

Sekretariatsleder, Danmarks Bløderforening

BENEFITS OF THE SPONSORSHIP

Programme:

EHC CONFERENCE

4-6 October 2019

Skopje, North Macedonia

PRELIMINARY PROGRAMME

08.00-19.00 Exhibition and Registration & Hospitality Desk

08.00-09.30 General Assembly (NMOs only)

09.30-10.00 *Tea/Coffee – Exhibition Area – iPad raffle*

10.00-12.00 General Assembly (NMOs only)

12.00-13.00 *Buffet Lunch*

13.00-13.45 Opening

Chair: Brian O'Mahony

13.00-13.15 Haemophilia Care in Macedonia, a clinician overview

Dr Violeta Dejanova-Ilievska

13.15-13.30 Life with haemophilia in Macedonia, a patient perspective

Bojan Chunde

13.30-13.45 30 Years of the EHC

Brian O'Mahony

13.45-15.00 Overview of new treatments in haemophilia patients with and without inhibitors

Co-Chairs: Dan Hart & Thomas Sannié

13.45-14.15 EHL: experiences with Fc-fusion, albumin-fusion and PEG products in haemophilia A and B in Europe

Johannes Oldenburg

14.15-14.45 How prophylaxis is changing in haemophilia

Beatrice Nolan

14.45-15.00 Discussion

15.00-16.15 Industry symposium 1 - Novo Nordisk on Women and Bleeding Disorders

16.15-16.45 *Tea/Coffee – Exhibition Area*

16.45-18.00 Industry symposium 2 - Sobi

18.00-18.45 Reception and Tapas

18.45-19.00 Conference Opening and Welcome

Brief welcome by Cvetanka Nakeska, President, Hemolog

Minister of Health (TBC)

Brief welcome by Brian O'Mahony, President, EHC

19.00-20.00 Youth Debate

20.00-22.30 Buffet Supper

HCV Film; Women's Film; Lithuanian Film

08.00-19.00 Exhibition and Registration & Hospitality Desk

08.30-09.45 Industry Symposium 3 - Sanofi

09.45 -10.15 *Tea/Coffee – Exhibition Area*

10.15-11.45 Quality of life & patient experience on first available non-replacement therapy

Co-Chairs: Flora Peyvandi & Miguel Crato

2

10.15-10.35 Patient experience on Emicizumab

Radoslaw Kaczmarek

10.35-11.05 Clinician management with Emicizumab

Dan Hart

11.05-11.25 Safety evaluation and surveillance of Emicizumab in Europe

Flora Peyvandi

11:25-11:45 Discussion

11:45-13:00 Industry Symposium 4 - BioMarin

13:00-14:00 *Buffet Lunch – Exhibition Area*

14:00-16:00 Scientific updates: novel therapies in other bleeding disorders

Co-Chairs: Olivia Romero-Lux & Flora Peyvandi

14:00-14:30 Prophylaxis in RBDs: What are RBD and when is prophylaxis needed

Roseline d'Oiron

14:30-15:00 Prophylaxis in VWD: Focus on diagnosis and treatment

Mike Laffan

15:00-15:30 Gene therapy in RBDs - are we there, is there any plan? (incl. FVII)

Ted Tuddenham

15:30-15:45 Management of women with fibrinogen deficiency

Giancarlo Castaman

15:45-16:00 Discussion

16:00-16:30 *Tea/Coffee & Poster Session – Exhibition Area*

16:30-17:45 Industry Symposium 5 - Roche

19:00-19:30 Coach Departure for Dinner

20:00-24:00 Conference Dinner

08:00-13:00 Exhibition and Registration & Hospitality Desk

08:30-10:15 Scientific updates: gene therapy

Co-chairs: Brian O'Mahony and Glenn Pierce

08:30-09:00 Overview of latest developments in gene therapy clinical trials

Flora Peyvandi

09:00-09:30 Regulatory perspective on gene therapy

Glenn Pierce

09:30-10:00 Patient perspectives on gene therapy

Radoslaw Kaczmarek

10:00-10:15 Discussion

10:15-10:45 *Tea/Coffee – Exhibition Area*

10:45-12:00 Industry Symposium 6 - Bayer

12:00-13:45 Creating a mind-shift: preparing and shaping the future

Co-Chairs: Radoslaw Kaczmarek & Johannes Oldenburg

12:00-12:30 Haemophilia Care in Europe - and future measurements

Declan Noone

12:30-13:00 Ensuring sustainability: how to improve treatments without increasing costs

Johannes Oldenburg

13:00-13:30 Future role haemophilia societies in the era of novel products: two perspectives

Brian O'Mahony and Thomas Sannié

13:30-13:45 Discussion

13:45-14:00 Closing remarks – *followed by light lunch*

Brian O'Mahony, President, EHC

Cvetanka Nakeska, President, Hemolog